Alexandre Sepriano

Rheumatologist MD PhD | 2019-2020 Chair of @EMEUNET | 2023-2025 Leader young @Official_ASAS | Interests: SpA/RA diagnosis/outcomes, epidemiology, biostatistics

[ARP Rheumatology @ARPrheumatology]

📣 Coming soon…

ARP Rheumatology x @SPReumatologia are launching a new initiative to train the next generation of scientific reviewers

If you're an SPR member interested in peer review & publishing — stay tuned.

🔜 Announcement very soon

#Rheumatology #PeerReview #SPR #ARP

[ARP Rheumatology @ARPrheumatology]

We are delighted to welcome Prof. @AlexSepriano as Methodological & Statistical Reviewer

A former Editor-in-Chief (2021–2025 and expert in epidemiology, biostatistics, and imaging outcomes, he strengthens our commitment to research excellence

Welcome back! 👏📊

[ARP Rheumatology @ARPrheumatology]

🧬 Rheumatoid nodules can be refractory—or even worsen—despite good joint control in RA.

📉 New case evidence shows cutaneous & pulmonary nodule regression with upadacitinib
➡️ Suggesting JAK inhibition effects beyond synovitis

🔗https://t.co/0egvaMkE8T

[ARP Rheumatology @ARPrheumatology]

🌟 Thank you to the Top Reviewers of ARP Rheumatology 2025

Your expertise and dedication to rigorous peer review help advance excellence in rheumatology research 🔬📘
Thank you for your invaluable contribution to advancing excellence in rheumatology research 💙

[ARP Rheumatology @ARPrheumatology]

Season’s Greetings from ARP Rheumatology ✨

Grateful to our amazing community for another year of collaboration and science.

Wishing you happy holidays and a healthy New Year! 📷 🌟

[CAUSALab @CAUSALab]

Last month, Sophia Rein was awarded a grant during the 2025 ADIA Lab symposium.

‘Causal AI for the Generation of Real-World Evidence from Healthcare Data’ will support software development for Causal AI (combining the g-formula with deep learning). Congrats, Sophia!

[Dr Ai Lyn Tan @DrAiLynTan]

Difficult-to-manage #PsoriaticArthritis
Include drivers such as
▶️Inflammation
▶️Comorbidities
▶️Psychosocial or other factors

Treatment-refractory PsA
▶️Persistent disease activity
▶️Objective evidence of active inflammation

👉🏽https://t.co/ED1YO8Grst
via @eular_ARD @eular_org

[ARP Rheumatology @ARPrheumatology]

🩺 Clinical Case Challenge
A 62-year-old woman presents with:
🫗 Bilateral parotid swelling
👁️ Dry eyes/mouth
🧠 Fatigue & weight loss
🧪 Labs: cytopenia, ↓complement, ↑ACE, ↑β₂-microglobulin
📸 Imaging: enlarged parotids + lymphadenopathy
⭐️ What’s the most likely diagnosis?

[ARP Rheumatology @ARPrheumatology]

🚨 New editorial in ARP Rheumatology: 5 years at a glance
📖 309 articles
🌍 ~50% international
⏱️ 36% faster publication
🔗 20 https://t.co/4sf7YZYIRR studies
🌐 Expanded digital & SM presence

Read 👉 https://t.co/jXsgiqRc5H

[ARP Rheumatology @ARPrheumatology]

📰 Don’t miss this month’s Editor’s Choice selected by Prof @TaniaLSantiago ✨

📌 PORTRESS: first nationwide registry for Sjögren’s in Portugal 🇵🇹
📌 Cervical CPPD
📌 ASAS definition of D2M & TR axSpA: first real-world insights
🔗 Read FREE: https://t.co/DILDdhLdQU

[ARP Rheumatology @ARPrheumatology]

📢Online First

Pemphigus foliaceus case with atypical hypocomplementemic urticarial vasculitis

Findings: hypocomplementemia + thrombocytopenia + hepatomegaly → B-cell lymphoproliferative disorder

⚠️ Vasculitic lesions may signal malignancy
🔗 https://t.co/k0lEc5i4zS

[ARP Rheumatology @ARPrheumatology]

✨The 2024 IF for ARP Rheumatology is 1.4!
📈 Our first total IF under the new name keeps the growth from 1.375 in 2022, securing a solid Q3 position.
🙏 Thank you to our authors, reviewers, Associate Editors & community for making this possible — and here’s to more growth ahead!

[ASAS @Official_ASAS]

It’s World AS Day!

How are you spreading awareness about axial spondyloarthritis today? Share your activities in the comments.

Thank you to everyone raising awareness and driving change today!

#WorldASDay2025 #LaceUpForAxSpA #EverydayChallenges

[ASAS @Official_ASAS]

New from the Slide Library: ASAS publication from @AlexSepriano et al

Higher ASDAS was longitudinally associated with higher spinal radiographic progression in patients with r-axSpA independently of treatment with TNFi.

👉 https://t.co/k0uYlFEWRg

[ASAS @Official_ASAS]

📣 MORE NEWS FROM ASAS
Congratulations to Prof. Raj Sengupta on his election to the ASAS Executive Committee!

We are also pleased to announce Prof. Pedro Machado’s new role as Executive Secretary of the ASAS Executive Committee.

#asas2025 #asa30yrs

[ASAS @Official_ASAS]

Mark your calendars for an essential session at the ASAS Core Course! Dr. Baraliakos will present his viewpoint on 'Rethinking Structural Progression in axSpA: A Balanced Approach.'
#SpA #Rheumatology #ASASCoreCourse #StructuralProgression"

[ASAS @Official_ASAS]

News from the ASAS annual meeting held in Barcelona:

Denis Poddubnyy and Wilson Bautista-Molano were elected as incoming ASAS Executive Committee members

[ASAS @Official_ASAS]

A big thank you to Mikhail Protopopov and Alexandre Sepriano for their exceptional leadership during their two-year term with Young ASAS! 🙌✨

#asas2025 #asa30yrs

[ASAS @Official_ASAS]

📣 NEWS FROM ASAS

We welcome incoming Young ASAS Leaders, Clementina Lopez Medina and Murat Torgutalp.

#asas2025 #asa30yrs

[ASAS @Official_ASAS]

📣 The Core Course on Spondyloarthritis has been granted 8 European
CME credits.

👉 https://t.co/aXMc2K5y96
#SpA #Rheumatology #ASASCoreCourse